Carcinoid Heart Disease: a Review.
Faidon-Marios LaskaratosJoseph DavarChristos ToumpanakisPublished in: Current oncology reports (2021)
CHD can affect up to 50% of NET patients with carcinoid syndrome. However, it is often not screened for appropriately and recognised late when patients become symptomatic. A screening strategy with biomarkers and multimodality imaging is necessary for early recognition. Management by an experienced multidisciplinary team with appropriate medical therapeutic strategies and where indicated surgical intervention is needed to optimise clinical outcomes. CHD is a poor prognostic factor, but recently, outcomes have improved due to the multidisciplinary approach and centralised care of CHD-NET patients.
Keyphrases
- prognostic factors
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- healthcare
- quality improvement
- palliative care
- peritoneal dialysis
- type diabetes
- metabolic syndrome
- case report
- patient reported outcomes
- mass spectrometry
- chronic pain
- skeletal muscle
- photodynamic therapy
- glycemic control